Cardinal Health stock: UBS keeps USD 295.00 target for Cardinal Health stock

Published on 10/19/2026 at 15:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardinal Health reports results on November 5, 2026 before trading. Cardinal Health stock costs EUR 222.95 on October 19, 2026 at 3:16 p.m. CEST.

Analyst target and reporting date

UBS maintained a USD 295.00 target for Cardinal Health on October 16, 2026.
Cardinal Health is scheduled to report fiscal first-quarter results on November 5, 2026.
Cardinal Health stock costs EUR 222.95 at Lang & Schwarz on October 19, 2026 at 3:16 p.m. CEST.
Cardinal Health carries a P/E ratio of 35.14 as of October 16, 2026.

Isometrische 3D-Illustration der Pharma-Lieferkette von Produktion bis Apotheke — Isometrisches 3D-Diagramm der Lieferkette von Cardinal Health Inc. – Medizinprodukte ISIN US14149Y1082, Illustration mit AI erstellt.

UBS maintained a Buy rating and a USD 295.00 price target for Cardinal Health on October 16, 2026, according to Markets Insider. The target stood above the USD 254.06 closing price cited for October 16, 2026.

Cardinal Health has a clear calendar marker ahead. The company plans to report fiscal first-quarter 2027 results on November 5, 2026, before trading begins on the New York Stock Exchange, according to its newsroom.

Revenue growth sets the scale

Cardinal Health reported fiscal 2026 revenue of USD 254.2 billion for the year ended June 30, 2026. That was higher than USD 222.6 billion in fiscal 2025, while diluted earnings per share rose from USD 6.45 to USD 7.23. The figures come from the company's annual financial statements.

The latest quarterly benchmark was also substantial. Cardinal Health reported revenue of USD 63.67 billion and earnings per share of USD 2.91 for the quarter reported on August 11, 2026, according to MarketBeat. Revenue increased 5.80 percent year over year, while earnings per share exceeded the cited consensus estimate of USD 2.42.

Valuation and peer scale

As of October 16, 2026, Cardinal Health had a market capitalization of USD 58.8 billion, a P/E ratio of 35.14 and a 52-week range of USD 155.84 to USD 258.30. The USD 254.06 closing price was near the upper end of that range.

Comparison with peers

Cardinal Health (NYSE, USD): plus 0.14 percent, P/E 35.14, market capitalization USD 58.8 billion

McKesson (NYSE, USD): plus 0.62 percent, P/E 26.89, market capitalization USD 117.2 billion

Cencora (NYSE, USD): minus 0.14 percent, P/E 25.33, market capitalization USD 65.1 billion

Cardinal Health stock in euros

At Lang & Schwarz, Cardinal Health stock was trading at EUR 222.95 on October 19, 2026 at 3:16 p.m. CEST. The bid was EUR 220.80 and the ask was EUR 225.10.

The latest market picture leaves the November reporting date as the next concrete event. The UBS target and the fiscal 2026 revenue base provide the two main reference points for assessing the stock's valuation without turning them into a recommendation.

The further course of trading is shown by the continuously updated real-time quote of Cardinal Health stock.